Latest Shinobi Therapeutics News & Updates

See the latest news and media coverage for Shinobi. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Shinobi Therapeutics (Shinobi)

Developer of immune-evasive induced pluripotent stem cell therapies

shinobitx.com
Headquarters
South San Francisco, United States
Founded year
2023
Company type
Private company
Number of employees
41–50
Industry
Pharmaceuticals

Last updated

Latest news about Shinobi Therapeutics (Shinobi)

In short: Shinobi reported preclinical validation of Katana and advanced two iPSC therapies toward the clinic.

Company announcements

Shinobi

Japan approves two iPSC-based cell therapy products

Sumitomo Pharma's Racthera and Cuorips gain approval, opening a new drug modality. Shinya Yamanaka's induced pluripotent stem cell discovery moves regenerative medicine from theory to clinic.

Shinobi

Shinobi Therapeutics launches with $51M Series A

Proceeds fund its Katana iPS-T cell platform and first GPC3+ solid tumor program toward the clinic; EQT Life Sciences, F-Prime and Eight Roads Ventures Japan led.

Unlock all announcements with a

Media coverage

BioWorld

Shinobi Therapeutics launches with $51M series A to advance iPS-T cell therapy platform

Japan-California startup Shinobi Therapeutics Inc. has emerged from stealth mode with a $51 million series A round to advance its first off-the-shelf induced pluripotent stem...

Unlock all articles with a

Never miss news about Shinobi

Track Shinobi and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.